Short answer
Trevi Therapeutics, Inc. (TRVI) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for the quarter ended September 30, 2026.
Trevi Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for the quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1, relevant for assessing Trevi’s operating performance and financial position
Item EX-99.1 · Exhibit EX-99.1
- Cash, equivalents and marketable securities $299.4M, supporting runway into 2030 and key Haduvio clinical milestones
- Phase 3 OCEAN-2 initiated for IPF cough, with topline results expected in second half 2027
- FDA alignment supports Phase 2 non-IPF ILD trial launch in Q1 2027, testing 54 mg BID and 27 mg BID
- Q3 net loss $21.5M versus $11.8M, with R&D rising to $19.1M from $10.1M as clinical spending accelerates
- USPTO Notice of Allowance could provide patent protection through 2041 for hepatically impaired non-IPF ILD patients
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Trevi Therapeutics, Inc. 8-K filings
Get the next TRVI 8-K as it lands
Follow TRVI for push alerts, or ask the research agent what this filing means.